First Test for Amgen: Fix Horizon’s Growth Problem

[ad_1] Markets Heard on the Street Sales of Horizon’s thyroid-eye disease drug Tepezza have plateaued, a challenge its new owner will need to contend with [ad_2] Source link

WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon Therapeutics

[ad_1] WSJ News Exclusive Business U.S. biotechnology company was the last of three suitors standing in an auction for Horizon [ad_2] Source link